However, in people with mild cognitive impairment, the presence of depressive symptoms was tied to a lower likelihood of amyloid pathology (OR 0.73, 95% CI 0.61-0.89, P =0.001), Oomens and colleagues ...
Even light-intensity activities such as walking can reduce one’s risk for clinical depression. So, what are the most common ...
CIII nasal spray for adults living with major depressive disorder who have had an inadequate response to at least two oral ...
Data on almost 57,000 people from 65 countries suggests that the Satisfaction With Life Scale (SWLS)—a widely used research ...
After briefly going dark in the U.S., TikTok is back online following an executive order. That’s not good for young users, ...
Johnson & Johnson has received FDA approval for Spravato nasal spray as the first and only monotherapy for adults with treatment-resistant depression.
Johnson & Johnson has announced the FDA’s approval of a first-of-its-kind, esketamine nasal spray called Spravato for the ...
The FDA has approved a supplemental new drug application for Spravato, an esketamine nasal spray that can be used as ...
The FDA approves Johnson & Johnson's sNDA for Spravato as a monotherapy for adults with treatment-resistant depression.
Esketamine, the active ingredient in Spravato, is a non-selective, non-competitive antagonist of the NMDA receptor, a known ...
Major depressive disorder (MDD) is a debilitating mental health condition characterized by persistent low mood, loss of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback